Funder
Shanghai Clinical Research Center
Reference35 articles.
1. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients;Baheti;Antimicrob. Agents Chemother.,2011
2. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults;Barditch-Crovo;Antimicrob. Agents Chemother.,2001
3. Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women;Baxi;AIDS.,2014
4. Ways to fit a PK model with some data below the quantification limit;Beal;J. Pharmacokinet. Pharmacodyn.,2001
5. Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS clinical trials group study A5202;Bednasz;Antimicrob. Agents Chemother.,2019